Edition:
United States

Resmed Inc (RMD.N)

RMD.N on New York Stock Exchange

96.27USD
12:20pm EDT
Change (% chg)

$-0.29 (-0.30%)
Prev Close
$96.56
Open
$96.56
Day's High
$96.56
Day's Low
$95.64
Volume
42,465
Avg. Vol
207,755
52-wk High
$104.78
52-wk Low
$67.07

Select another date:

Thu, Apr 19 2018

BRIEF-Resmed Says Co Entered Certain Amended And Restated Credit Agreement, Dated As Of Closing Date

* RESMED SAYS ON APRIL 17, 2018 ('CLOSING DATE'), CO ENTERED CERTAIN AMENDED AND RESTATED CREDIT AGREEMENT, DATED AS OF CLOSING DATE - SEC FILING

BRIEF-ResMed Hires Bobby Ghoshal As First Chief Technology Officer

* RESMED HIRES BOBBY GHOSHAL AS FIRST CHIEF TECHNOLOGY OFFICER Source text for Eikon: Further company coverage:

BRIEF-ResMed Q2 Gaap Earnings Per Share $0.07

* ANNOUNCES RESULTS FOR THE SECOND QUARTER OF FISCAL YEAR 2018

NZ's Fisher & Paykel sues Resmed in Australia over patent dispute

New Zealand's Fisher & Paykel Healthcare filed a lawsuit in Australia on Tuesday against Resmed Inc alleging the medical device manufacturer's respiratory treatment products violate four Fisher & Paykel patents.

UPDATE 1-NZ's Fisher & Paykel sues Resmed in Australia over patent dispute

Dec 12 New Zealand's Fisher & Paykel Healthcare filed a lawsuit in Australia on Tuesday against Resmed Inc alleging the medical device manufacturer's respiratory treatment products violate four Fisher & Paykel patents.

NZ's Fisher & Paykel sues Resmed in patent dispute

Dec 12 New Zealand's Fisher & Paykel Healthcare filed a lawsuit in Australia on Tuesday against Resmed Inc alleging the medical device manufacturer's respiratory treatment products violate four Fisher & Paykel patents.

BRIEF-Resmed Inc elects Karen Drexler to its board of directors

* Resmed elects Karen Drexler to its board of directors Source text for Eikon: Further company coverage:

Fisher & Paykel says UK court rules rival Resmed's patent is invalid

WELLINGTON New Zealand's Fisher & Paykel Healthcare said on Monday that it could continue to sell its sleep apnea masks in Britain as a UK court had ruled that rival Resmed Inc's patent was invalid.

BRIEF-Resmed updates on United Kingdom case with Fisher & Paykel​

* Ruling has no impact on Resmed's commercial operations in UK​

Select another date: